

A β Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease

**Victor L. Villemagne · William E. Klunk ·
Chester A. Mathis · Christopher C. Rowe ·
David J. Brooks · Bradley T. Hyman ·
Milos D. Ikonovic · Kenji Ishii · Clifford R. Jack ·
William J. Jagust · Keith A. Johnson ·
Robert A. Koeppe · Val J. Lowe · Colin L. Masters ·
Thomas J. Montine · John C. Morris ·
Agneta Nordberg · Ronald C. Petersen ·
Eric M. Reiman · Dennis J. Selkoe · Reisa A. Sperling ·
Koen Van Laere · Michael W. Weiner ·
Alexander Drzezga**

Published online: 5 January 2012

© The Author(s) 2012. This article is published with open access at Springerlink.com

The editorial by Moghbel and colleagues published in this issue of the *European Journal of Nuclear Medicine and Molecular Imaging* raises a number of concerns with regard to amyloid-beta (A β) imaging [1]. We appreciate the

opportunity to address and clarify these concerns by referring to the scientific literature. There are several issues raised by Moghbel and colleagues which we acknowledge require careful consideration, further discussion, and research, including

V. L. Villemagne · C. C. Rowe
Department of Nuclear Medicine and Centre for PET,
Austin Health,
Heidelberg, VIC, Australia

V. L. Villemagne
e-mail: villemagne@petnm.unimelb.edu.au

C. C. Rowe
e-mail: christopher.rowe@austin.org.au

W. E. Klunk
Department of Psychiatry,
University of Pittsburgh School of Medicine,
Pittsburgh, PA, USA
e-mail: klunkwe@upmc.edu

C. A. Mathis
Department of Radiology,
University of Pittsburgh School of Medicine,
Pittsburgh, PA, USA
e-mail: mathisca@upmc.edu

D. J. Brooks
Department of Medicine, Imperial College London,
London and GE Healthcare, Medical Diagnostics,
Amersham, UK
e-mail: david.brooks@csc.mrc.ac.uk

B. T. Hyman
Department of Neurology, Harvard University,
Boston, MA, USA
e-mail: bhyman@partners.org

M. D. Ikonovic
Department of Neurology, University of Pittsburgh,
Pittsburgh, PA, USA
e-mail: ikonovicmd@upmc.edu

K. Ishii
Positron Medical Center/Clinic,
Tokyo Metropolitan Institute of Gerontology,
Itabashi-ku, Tokyo, Japan
e-mail: ishii@pet.tmig.or.jp

C. R. Jack · V. J. Lowe
Department of Radiology, Mayo Clinic,
Rochester, MN, USA

C. R. Jack
e-mail: jack.clifford@mayo.edu

V. J. Lowe
e-mail: vlowe@mayo.edu

nonspecific white matter retention, the diagnostic value of A β imaging, and the role of A β pathology in disease generation. However, the editorial by Moghbel and colleagues brings into question the very feasibility of imaging A β in the brains of living humans [1]. Many of the issues raised in the editorial have been extensively researched and discussed in various scientific venues and publications over the past decade. However, it may be worthwhile to communicate these findings to a larger community, including scientists not active in this particular field of research. Thus, to avoid further misunderstandings and foster discussion based upon common grounds of knowledge in the future, we will try to address the issues raised by Moghbel and colleagues point by point and summarize the corresponding evidence in the following order: (1) alleged anomalies in the distribution of A β radiotracers, (2) perceived difficulties in visualizing A β plaques, (3) concerns

about the binding properties of A β radiotracers to plaques, and (4) questions regarding the theoretical basis of A β imaging.

Alleged anomalies in the distribution of A β radiotracers

Moghbel and colleagues point out two issues regarding the regional distribution of A β radiotracers. One is a limitation of all existing A β radiotracers: nonspecific white matter retention. This phenomenon is well known, having previously been demonstrated in *in vitro* studies with human brain (see Fig. 4 of [2], Figs. 1C&D of [3], and Fig. 2 of [4]), in animal studies, (see Fig. 3 of [5]), and from the very beginning of *in vivo* human studies (see Fig. 3B of [4]). In hundreds of subjects, it has been shown that the level of this

W. J. Jagust
Public Health and Neuroscience, University of California,
Berkeley,
Berkeley, CA, USA
e-mail: jagust@berkeley.edu

K. A. Johnson
Departments of Radiology and Neurology,
Harvard Medical School,
Boston, MA, USA
e-mail: kajohnson@partners.org

R. A. Koeppe
Department of Radiology, University of Michigan,
Ann Arbor, MI, USA
e-mail: koeppe@umich.edu

C. L. Masters
Mental Health Research Institute, University of Melbourne,
Parkville, VIC, Australia
e-mail: c.masters@unimelb.edu.au

T. J. Montine
Department of Pathology,
University of Washington School of Medicine,
Seattle, WA, USA
e-mail: tmontine@uw.edu

J. C. Morris
Department of Neurology,
Washington University School of Medicine,
St. Louis, MO, USA
e-mail: morrisj@abraxas.wustl.edu

A. Nordberg
Department of Neurobiology, Care Sciences and Society,
Karolinska Institute, Karolinska University Hospital,
Huddinge, Stockholm, Sweden
e-mail: agneta.k.nordberg@ki.se

R. C. Petersen
Department of Neurology, Mayo Clinic College of Medicine,
Rochester, MN, USA
e-mail: peter8@mayo.edu

E. M. Reiman
Banner Alzheimer's Institute, University of Arizona,
Phoenix, AZ, USA
e-mail: eric.reiman@bannerhealth.com

D. J. Selkoe · R. A. Sperling
Department of Neurology, Harvard Medical School,
Boston, MA, USA

D. J. Selkoe
e-mail: dselkoe@rics.bwh.harvard.edu

R. A. Sperling
e-mail: reisa@rics.bwh.harvard.edu

K. Van Laere
Division of Nuclear Medicine, University Hospitals Leuven,
Leuven, Belgium
e-mail: koen.vanlaere@uzleuven.be

M. W. Weiner
Radiology, Medicine, Psychiatry, and Neurology,
University of California,
San Francisco, CA, USA
e-mail: michael.weiner@ucsf.edu

M. W. Weiner
Center for Imaging of Neurodegenerative Diseases,
San Francisco Veterans Affairs Medical Center,
University of California,
San Francisco, CA, USA

A. Drzezga (✉)
Department of Nuclear Medicine,
Technische Universität München,
Munich, Germany
e-mail: a.drzezga@lrz.tu-muenchen.de

A. Drzezga
e-mail: a.drzezga@lrz.tum.de

nonspecific white matter retention does not differ between Alzheimer's disease (AD) patients and normal controls [6–9]. Given that regional cerebral blood flow in white matter is approximately 40–50% of that in neocortex [10, 11], slower clearance of tracers [12] likely contributes to A β radiotracer retention in white matter [4, 13]. This nonspecific retention continues to represent a challenge to optimizing the analysis of A β imaging positron emission tomography (PET) data. It is true that spillover can occur from this nonspecific retention into neighboring gray matter (and vice versa when gray matter contains high amounts of fibrillar A β). However, it should be mentioned that due to the relatively small width of the cortical gray matter, which can be below the resolution of a PET scanner, the partial volume effect is not a problem unique to A β imaging but affects PET imaging procedures of the brain in general. Furthermore, in Fig. 2 of Moghbel et al., a representation of the partial volume effect is given that is not appropriate for A β imaging. Moghbel et al. refer to work in malignant lung lesions where the intensity differences are indeed huge and “overwhelming” [14]. In contrast, the typical retention of A β radiotracers in gray matter is not a small fraction of an overwhelming level of white matter retention as depicted, but at least comparable to threefold higher in typical A β -positive scans. Nevertheless, it is clear that the white matter uptake and the corresponding partial volume effects may lead to inaccuracies in the precise quantification of cortical tracer retention and thus assessment of cortical A β . While common to all A β radiotracers, this is more noticeable in currently published studies using ^{18}F -labeled A β radiotracers, which appear to generally show somewhat higher white matter retention as compared to ^{11}C -labeled Pittsburgh Compound-B (PiB) [4, 7, 9, 15–17]. However, this limitation has not proven to be a major hurdle to the quantitation of A β deposits in cortical gray matter, neither in the *in vivo*/postmortem cross-validation studies, nor in studies on the predictive value of the A β imaging findings, with regard to future cognitive decline. Nevertheless, there is room for further improvement in this context with regard to the development of tracers with less white matter retention and of image evaluation techniques (such as partial volume correction algorithms/volume of interest-based techniques for selective identification of gray matter uptake) [18–20]. Finally, it needs to be emphasized that for many clinical purposes, answering the question of the general presence of A β pathology in the brain with YES or NO by visual assessment will be of higher priority than absolute quantification and localization of these abnormalities. For example, in routine clinical practice, fluorodeoxyglucose (FDG) PET data of the brain are read without partial volume correction and the interpretation is usually established without absolute quantification of the findings.

A second alleged discrepancy between A β tracer retention and A β pathology—the claim that the frontal lobes do


not harbor very high A β deposition in AD—is contradicted by a wealth of existing data. Thal et al. have clearly demonstrated heavy and early frontal A β deposition [21]. In their classic 2002 paper, this group (led by Heiko Braak) stated that in the earliest phase of A β deposition (phase 1) “*there are A β deposits in the frontal, parietal, temporal, or occipital neocortex*” [21] and Fig. 2 of this group's 1997 paper based on the examination of 2,661 brains clearly shows early and predominant basal frontal and anterior temporal A β deposition [22] (Fig. 1).

Numerous other neuropathological studies recapitulate these findings. In fact, the lead author of the paper that Moghbel et al. lean upon most heavily [23] later published a report showing that very high plaque density is found in the frontal cortex in AD [24]. An even more recently published work by this group demonstrated good correlation of an ^{18}F A β tracer to pathologically determined A β load in biopsies of the frontal cortex [25]. Despite the fact that neuropathological studies consistently detect a high A β plaque load in frontal cortex, neuropathological measures of percent plaque area are only semiquantitative and are complicated by variations caused by the fluorescence properties of the dyes used or secondary reactions used to amplify A β -antibody binding. Therefore, this may not be the most appropriate comparison to A β imaging. A more appropriate postmortem analysis would be truly quantitative assessments such as enzyme-linked immunosorbent assay (ELISA) analysis of A β load [26, 27]. In their benchmark study of 79 postmortem brains, Näslund et al. clearly show that frontal cortex typically contains two- to fourfold higher levels of total A β than temporal, entorhinal, parietal, or visual cortices [26]. In summary, the contention by Moghbel and colleagues that the frontal lobe is not a prominent site of A β deposition is inconsistent with the current state of knowledge regarding the neuropathology of AD.

The suggestion by Moghbel and colleagues that congophilic angiopathy (CAA) could be responsible for A β tracer retention in the frontal cortex also does not follow from the neuropathology literature. Several studies (including a recent one they cite [28]) clearly identify the occipital lobe as the site of highest A β deposition in CAA, but the occipital lobe is one of the lowest neocortical sites of A β radiotracer retention in AD [6, 29].

Moghbel et al. also claim that structural and functional changes such as regional atrophy, hypoperfusion, or hypometabolism should serve as a predictor of regional A β pathology. However, evidence that these processes are associated with regional postmortem A β pathology is sparse. For example, while brain atrophy may indeed occur in some areas of the brain affected by A β pathology, the data suggest that these abnormalities are sequential, and that A β deposition precedes synaptic dysfunction and neuronal loss [30–32], which are then evidenced as structural

Fig. 1 “Development of amyloid deposits in 2,661 nonselected autopsy cases. The first line displays the frequency of cases devoid of changes in relation to the total number of cases in the various age categories. The second, third, and fourth lines are similarly designed, and show the evolution of the AD-related changes. The dark areas of the columns refer to subgroups showing the presence of neurofibrillary changes.” (reproduced with permission from *Neurobiol Aging*, [22])




changes [33]. This may very well explain the regional discrepancies between patterns of atrophy and $A\beta$ deposition detected by in vivo imaging studies [34]. At any rate, these considerations revolve around the interaction of different neurodegenerative pathologies and do not relate to the value of $A\beta$ imaging to accurately measure the presence of $A\beta$ in the brain.

The strongest proof of the feasibility of $A\beta$ imaging to accurately measure $A\beta$ deposition in vivo is founded on a wealth of detailed $A\beta$ PET-neuropathology correlative studies that demonstrate the close match between in vivo $A\beta$ radiotracer retention and postmortem $A\beta$ pathology as assessed by ELISA, immunohistochemistry, Bielschowsky silver staining, or quantitative in vitro assessment of tritiated PiB binding [25,

35–43] (Fig. 2). Further support is added by the fact that high retention of $A\beta$ radiotracers closely corresponds with: (1) low CSF $A\beta$ levels, (2) presence of the apolipoprotein E $\epsilon 4$ allele, and (3) increasing age [44–47].

To make this argument even stronger, those subjects with a different regional distribution of $A\beta$ in the brain such as those carrying one of the mutations associated with autosomal dominant AD [48–50], or familial British dementia [51], or subjects with posterior cortical atrophy [52–55] or CAA [56, 57] show a different regional distribution of PiB retention. If the retention of $A\beta$ radiotracers was determined by nonspecific factors as much as Moghbel and colleagues suggest, then all scans would look relatively similar. The sharp distinction between the regional pattern of PiB

Fig. 2 Correlations of the in vivo PiB distribution volume ratio (DVR) values with postmortem quantifications of [^3H]PiB binding (*E*) and total insoluble A β (A β_{1-40} +A β_{1-42}) peptide levels (*F*) in 19 brain regions from fresh-frozen tissue from the right hemisphere of the same Alzheimer's disease subject. (reproduced with permission from *Brain*, [36])



retention in many presenilin-1 mutation carriers [48] and sporadic AD (Fig. 3)—corresponding to the known patterns of A β aggregation in their brains—makes a convincing argument for specific A β -driven retention of A β PET tracers.

Perceived difficulties in visualizing A β plaques

Moghbel and colleagues raise the concern that A β plaques in the brain are too small to allow in vivo imaging by means of PET. This argument would not only render A β imaging

as impractical, but it would argue against the possibility of imaging structures/processes of even smaller size (i.e., molecular imaging in general), such as neuronal glucose metabolism (regularly imaged with FDG) or the receptor density on cell membranes. A β imaging does not attempt to resolve an individual 50–100 μm A β plaque. That futile effort would indeed be thwarted by the limited resolution of PET and the partial volume effects described. However, partial volume effects not only decrease the signal within a small structure such as a plaque due to low-signal bleed-in, but partial volume effects also increase the signal in the plaque penumbra by high-signal bleed-out. The net effect is a blurring of the signal on a submillimeter scale, but without significant loss of total signal on a larger scale. Like any other PET technique, A β imaging assesses the *average concentration* of A β radiotracer binding sites within a region of interest. Just as one dopamine receptor would be swamped by neighboring receptor-free tissue but millions of dopamine receptors produce a strong ^{11}C -raclopride signal in the striatum, also millions of fibrillar A β deposits produce a signal that is easily detectable in A β -laden parts of gray matter.

Another concern brought up by Moghbel and colleagues is based on the surprising and unsupported assumption that the mass of A β in mild cognitive impairment (MCI) would be 60-fold less than (i.e., 1–2% of) that in AD, thus not possibly providing enough target structures for successful imaging. This assumption is not supported by data of neuropathological studies. In contrast, the quantitative postmortem data of Näslund et al. showed that subjects who die at the Clinical Dementia Rating (CDR) 0.5 stage (typically considered MCI) had an A β load 25–76% of that seen in patients with established dementia (CDR of 1.0 or greater) [26].

Even in groups of autopsy cases consisting of early or mild-moderate AD, neocortical amyloid markers are not significantly different when compared to those in MCI cases [58]. A recent review summarized the extent of amyloid pathology in MCI relative to cognitively normal people and early AD [59].

There is ample A β in the neocortex of AD and MCI patients and many normal controls to be detected with A β




Fig. 3 Comparison of the regional distribution of PiB retention in a presenilin-1 mutation carrier (*left*) and a sporadic case of AD (*right*). The MRI is shown in *gray* and PiB retention is overlaid in a hot metal scale on transaxial (*top*), sagittal (*middle*), and coronal images (*bottom*)

radiotracers. The nominal concentration of A β in AD frontal cortex is $\sim 3 \mu\text{M}$ [26, 27, 60], which is about twofold the number of PiB binding sites measured in vitro under saturating conditions [60] (and in the mid-nanomolar range under non-saturating conditions [61]). This is several orders of magnitude higher than the concentration of many receptors successfully assessed by PET. A recent paper demonstrated that, even under non-saturating conditions, there are about the same number of binding sites available in frontal and temporal cortex in postmortem human AD tissue [~ 60 fmol/mg tissue (~ 60 nM)]. The authors concluded that “*the observed binding of [^{11}C]PiB to amyloid plaques in vitro in human AD tissue, but not in healthy controls, is in correspondence with in vivo studies of patients with AD. This radiotracer is therefore very suitable in the early diagnosis of AD and can be used for the detection of pathological changes before there is a significant loss in cognitive function.*” [61]. This, along with the high affinity of the PET radiotracers for A β , renders the concerns about visualizing A β plaques inconsistent with a wealth of existing data.

Concerns about the binding properties of A β plaques

Moghbel and colleagues also propose that there may be “*inherent difficulties of targeting fibrillar amyloid plaques, which are not as well-defined as the soluble forms of the protein.*” Since the soluble (including oligomeric) forms of A β are not well defined at all, it is difficult to interpret this concern. In principle, conversion of a number of available binding sites from a soluble to a more solid or immobile status would be expected to increase the binding of a suitable ligand. For example, decreasing the mobility of receptors by fixation to a solid support can increase the binding of ligands [62, 63] because of decreased entropy and increased rebinding of small molecule ligands [64]. Currently, there are no data to support the idea that A β radiotracer binding to insoluble A β fibrils is fundamentally different than any other binding interaction of a radioligand with specific binding sites on other proteins (many of which are relatively immobile because they are embedded in membranes). In fact, the binding of A β radiotracers to A β fibrils shows typical, reversible binding properties in in vitro kinetic binding analyses [18].

The authors point out that no in vivo studies using high doses of unlabeled A β PET ligand to compete off the specifically bound A β radiotracer have been performed to validate the specific and reversible nature of binding in humans. This is true and will likely remain true for two reasons: (1) the nominal concentration of A β radiotracer binding sites is on the order of $1 \mu\text{M}$ in AD cortex [26, 27, 60], requiring micromolar levels of unlabeled ligand to effectively compete off the A β radiotracer; and (2) none of

the A β tracers have been approved for human use at the doses required to achieve micromolar levels in brain. While it might be possible to perform such studies in animals, there are significant problems using A β radiotracers in transgenic mouse models of AD [60, 65], although some of these problems may be possible to overcome [66].

A more pertinent concern that Moghbel et al. correctly point out is that there are different tertiary forms of A β deposited in brain, such as the amorphous deposits in cerebellum which have very low affinity for all A β radiotracers. This conformational variability also may come into play in autosomal dominant forms of AD [48, 67] and in early stages of A β deposition [37], but the significance of non-fibrillar A β in typical, sporadic, late-onset AD is unknown. Studies assessing the selectivity of PiB for other aggregated misfolded proteins present in AD, such as tau/neurofibrillary tangles [36, 68] and α -synuclein/Lewy bodies [69, 70] utilizing in vitro methods that are more pertinent to PiB binding in vivo, have shown that in vivo cortical retention of ^{11}C -PiB primarily reflects fibrillar A β deposits. The potentially differential affinity of the A β tracers to various forms of A β deposits does not necessarily affect the clinical utility of A β imaging. For example, the case mentioned by Moghbel and colleagues [37] did not meet two commonly used sets of neuropathological criteria for AD [71, 72], because only sparse neuritic plaques and neurofibrillary tangles were present, although the case did meet the older Khachaturian criteria [73]. Nevertheless, it is important to keep in mind that different conformations of A β deposits in the brain [74] may affect the binding pattern of the tracers and that A β imaging modalities may not recognize all types of A β pathologies with equal sensitivity. This may be an interesting area of future research, to further improve the understanding of the quantitative information provided by in vivo A β imaging methods. However, any additional insights in this regard would rather lead to assigning a more specific information to the A β imaging signal than putting the general utility of this method into question.

Questions regarding the theoretical basis of A β imaging

Finally, Moghbel and colleagues broaden their concerns well beyond issues related to PET imaging by questioning the A β cascade hypothesis itself. This would imply that if A β deposition is not causative of AD, it is not worth measuring. In this context, it is important to draw a clear distinction between the value of A β imaging and the merits of the A β hypothesis—a hypothesis that remains supported by the bulk of existing data [75]. The basic feasibility of imaging AD pathology in vivo should not be confused with a discussion of the causal relevance of A β in AD. In isolation, A β imaging is not diagnostic, it is agnostic—that

is, agnostic to the role of A β deposition in AD. A β imaging was intended to assess the pathology of AD in vivo. This tool may ultimately be used to help prove or disprove the A β hypothesis of AD. The A β cascade hypothesis, though important, is not highly relevant to the feasibility and validity of A β imaging since, by definition, A β deposition remains a pathological hallmark of this disease.

Further, Moghbel et al. suggest that if A β deposition is causative, then the levels of A β in brain should correlate with cognition. Again, A β imaging is not a tool to assess cognition. In contrast, it may represent a tool to detect A β pathology independently and in particular before the onset of clinically significant cognitive symptoms. For example, a number of studies that have demonstrated the predictive value of A β pathology in subjects with MCI with regard to subsequent cognitive decline support this notion [76–79]. The long-recognized discrepancy between cognitive impairment and A β plaque burden in the brain [80] may be explained by three factors: (1) a dissociation in timing between early disease events and subsequent events that are more directly related to cognition [81]; (2) cognitive changes may be more related to the long-term, cumulative effects of soluble, oligomeric forms of A β (not apparent by routine neuropathology or imaged by current PET tracers) [82, 83]; and (3) the importance of cognitive reserve in the modulation of symptoms in the presence of brain pathology [84, 85].

Moghbel and colleagues further discuss the “*noteworthy rates of false-positive and false-negative PET scans using amyloid tracers*” [1]. This appears to reflect conceptual misunderstanding and terminological imprecision. A person with a positive A β PET scan who is negative for clinical AD should not be regarded as a “false-positive” but rather correctly classified as an “A β -positive” non-demented subject. This was clarified in the original report using PiB PET [4] as follows, “*Therefore, at the outset, it may be best to not equate amyloid deposition to clinical diagnosis. Rather than as a method of diagnosis, it might be best to first think of PiB retention more fundamentally as a method to detect and quantify brain β -amyloidosis, a term first used in reference to AD by Glenner [86].*” A β imaging simply detects cerebral β -amyloidosis. It does not provide a diagnosis by itself. It is only one tool to be used along with clinical assessment and other biomarker modalities to enhance our ability to provide earlier and more accurate diagnoses. The “false-positives” and “false-negatives” to which Moghbel et al. refer are mismatches between the presence of cerebral β -amyloidosis and symptoms of dementia. They are not false-positives and false-negatives for the presence of A β . The latter can only be determined by PET-neuropathology correlations and to date, there have been essentially no reported false-positives and only the rare false-negatives that would be expected when comparing an in vivo technique with a highly sensitive tissue stain [41, 87].

Summary

We acknowledge that there are a number of caveats with regard to the clinical value of A β imaging. This includes disorders other than AD which may show A β deposition (such as dementia with Lewy bodies), the unknown time to conversion in healthy A β -positive persons or the relative plateauing of the A β burden in later stages of disease [79, 87–90]. However, these caveats are not related to the proven functionality of the tracers and should not hamper the application and further evaluation of in vivo A β imaging with PET.

The fact that A β deposits can be detected by A β imaging in vivo is, in our opinion, a fact substantiated by a wealth of peer-reviewed data. ¹⁸F-Labeled A β imaging radiotracers may be approved for clinical use in the near future. If so, this will be the first PET radiopharmaceutical developed commercially and the first PET tracer approved for clinical use by the US Food and Drug Administration (FDA) since FDG. As such, it represents a landmark moment in the field of molecular imaging and should encourage further commercial investment and development in the field. The functionality, sensitivity, and specificity of A β plaque imaging agents has by now been demonstrated in a level of detail and reliability (including in vivo-to-postmortem autopsy correlations) that has not been required or provided for most other imaging tracers clinically used today. Many of the concerns raised by Moghbel and colleagues in their current editorial in the *European Journal of Nuclear Medicine and Molecular Imaging* have been resolved previously, and we attempted to summarize the available information on these issues, to allow a future rational discussion on common grounds of knowledge. As is the case for any clinical test, A β imaging does not represent a perfect tool and some justified concerns remain, such as the nonspecific white matter retention or the effects of atrophy and partial volume on quantification. However, none of these concerns reasonably question the general feasibility of A β imaging or have been demonstrated to hamper the value of this procedure for detection of fibrillar A β pathology. A discussion regarding clinical indications for A β imaging is as welcome and important as the debate about the causal role of A β pathology in the genesis of AD. However, both of these topics clearly need to be treated independently from the feasibility of A β imaging itself. Thus, we believe that the remaining issues do not justify a call to slow the clinical development of these radiotracers and to withhold the availability of this technology from those it could potentially help. In contrast, we believe that hindering the progress of this exciting new molecular imaging approach could send an erroneous and discouraging signal to groups interested in the development of other new diagnostic agents. The inability to obtain the information provided by A β imaging would most certainly slow

down the urgently needed progress in understanding the basics of neurodegeneration and in the development of new approaches aiming to treat these devastating disorders. A β imaging has been repeatedly held up as one of the major successes of the past decade in the fight against AD. Thus, rather than to unnecessarily question the general feasibility of A β imaging, we believe we should vigorously foster the application of this unique new tool to improve our understanding of AD pathophysiology, to aid clinical diagnosis, and to advance the development of effective therapy.

Acknowledgments We wish to thank Prof. R. E. Indeer, M.D. and Dr. B. Oarsback, Ph.D. for inspiration and advice.

Conflicts of interest This response represents a consensus opinion of all coauthors, is meant to apply to all current amyloid PET tracers equally, and is not meant to favor any one particular tracer over any other. Two coauthors (WEK and CAM) have a conflict of interest based on being coinventors of an amyloid imaging tracer licensed by GE Healthcare, several coauthors (AD, MDI, KI, WJJ, KAJ, WEK, VJL, CLM, CAM, AN, RCP, EMR, CCR, RAS, KVL, VLV, and MWW) have been paid consultants to or received research grant support from one or more of the companies developing commercial amyloid imaging tracers (AstraZeneca, Bayer Schering, GE Healthcare Merck and/or Avid/Lilly) and one coauthor (DJB) holds a part-time position as a Senior Neurologist with GE Healthcare. Six coauthors have no conflicts of interest relative to amyloid PET tracers (BTH, CRJ, RAK, TJM, JCM, DJS).

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

- Moghbel MC, Saboury B, Basu S, Metzler SD, Torigian DA, Långström B, Alavi A. Amyloid-beta imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies? *Eur J Nucl Med Mol Imaging* 2011. doi:10.1007/s00259-011-1960-4.
- Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, Hamilton RL, Ikonovic MD, DeKosky ST, Mathis CA. The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. *J Neurosci* 2003;23(6):2086–92.
- Fodero-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li QX, Masters CL, Cappai R, Villemagne VL. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. *J Nucl Med* 2009;50(2):198–204. doi:10.2967/jnumed.108.057984.
- Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. *Ann Neurol* 2004;55(3):306–19.
- Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. *J Med Chem* 2003;46(13):2740–54.
- Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolkowski SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, Dekosky ST, Halligan EM, Klunk WE. Frequent amyloid deposition without significant cognitive impairment among the elderly. *Arch Neurol* 2008;65(11):1509–17.
- Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Komer A, Minthon L, Garraux G, Nelissen N, Bormans G, Buckley C, Owenius R, Thurfjell L, Farrar G, Brooks DJ. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. *Ann Neurol* 2010;68(3):319–29.
- Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. *Lancet Neurol* 2008;7(2):129–35. doi:10.1016/S1474-4422(08)70001-2.
- Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasic JR, Ye W, Hilton J, Lyketos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). *J Nucl Med* 2010;51(6):913–20. doi:10.2967/jnumed.109.069088.
- Chou YC, Teng MM, Guo WY, Hsieh JC, Wu YT. Classification of hemodynamics from dynamic-susceptibility-contrast magnetic resonance (DSC-MR) brain images using noiseless independent factor analysis. *Med Image Anal* 2007;11(3):242–53.
- Liu P, Uh J, Devous MD, Adinoff B, Lu H. Comparison of relative cerebral blood flow maps using pseudo-continuous arterial spin labeling and single photon emission computed tomography. *NMR Biomed* 2011 [Epub ahead of print]. doi: 10.1002/nbm.1792.
- Ichise M, Golan H, Ballinger JR, Vines D, Blackman A, Moldofsky H. Regional differences in technetium-99m-ECD clearance on brain SPECT in healthy subjects. *J Nucl Med* 1997;38(8):1253–60.
- Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL. Imaging beta-amyloid burden in aging and dementia. *Neurology* 2007;68(20):1718–25. doi:10.1212/01.wnl.0000261919.22630.ea.
- Hickeson M, Yun M, Matthies A, Zhuang H, Adam LE, Lacorte L, Alavi A. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. *Eur J Nucl Med Mol Imaging* 2002;29(12):1639–47.
- Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O'Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reiningner CB, Fels L, Putz B, Rohde B, Masters CL, Rowe CC. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. *J Nucl Med* 2011;52(8):1210–7. doi:10.2967/jnumed.111.089730.
- Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reiningner C, Sabri O. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. *Lancet Neurol* 2011;10(5):424–35. doi:10.1016/S1474-4422(11)70077-1.
- Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, Joshi AD, Clark CM, Mintun MA, Pontecorvo MJ, Doraiswamy PM, Johnson KA, Skovronsky DM, Reiman EM. Using positron emission tomography and florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. *Arch Neurol* 2011;68:1404–11.
- Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolkowski SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA. Kinetic modeling of

- amyloid binding in humans using PET imaging and Pittsburgh Compound-B. *J Cereb Blood Flow Metab* 2005;25(11):1528–47.
19. Thomas BA, Erlandsson K, Modat M, Thurfjell L, Vandenberghe R, Ourselin S, Hutton BF. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. *Eur J Nucl Med Mol Imaging* 2011;38(6):1104–19. doi:10.1007/s00259-011-1745-9.
 20. Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, Eggers B, Sattler B, Schildan A, Hesse S, Meyer PM, Wolf H, Zimmermann T, Reischl J, Rohde B, Gertz HJ, Reininger C, Sabri O. Individualized quantification of brain beta-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. *Eur J Nucl Med Mol Imaging* 2011;38:1702–14. doi:10.1007/s00259-011-1821-1.
 21. Thal DR, Rüb U, Orantes M, Braak H. Phases of A β -deposition in the human brain and its relevance for the development of AD. *Neurology* 2002;58(12):1791–800.
 22. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. *Neurobiol Aging* 1997;18(4):351–7.
 23. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. *Cereb Cortex* 1991;1(1):103–16.
 24. Arnold SE, Han LY, Clark CM, Grossman M, Trojanowski JQ. Quantitative neurohistological features of frontotemporal degeneration. *Neurobiol Aging* 2000;21(6):913–9.
 25. Wolk DA, Grachev ID, Buckley C, Kazi H, Grady MS, Trojanowski JQ, Hamilton RH, Sherwin P, McLain R, Arnold SE. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. *Arch Neurol* 2011;68(11):1398–403. doi:10.1001/archneurol.2011.153.
 26. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. *JAMA* 2000;283(12):1571–7.
 27. Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC. Plasma A β levels do not reflect brain A β levels. *J Neuropathol Exp Neurol* 2007;66(4):264–71.
 28. Attems J, Quass M, Jellinger KA, Lintner F. Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology. *J Neurol Sci* 2007;257(1–2):49–55.
 29. Lowe VJ, Kemp BJ, Jack Jr CR, Senjem M, Weigand S, Shiung M, Smith G, Knopman D, Boeve B, Mullan B, Petersen RC. Comparison of 18F-FDG and PiB PET in cognitive impairment. *J Nucl Med* 2009;50:878–86.
 30. Drzezga A, Becker JA, Van Dijk KR, Sreenivasan A, Talukdar T, Sullivan C, Schultz AP, Sepulcre J, Putcha D, Greve D, Johnson KA, Sperling RA. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. *Brain* 2011;134(Pt 6):1635–46.
 31. Förster S, Grimmer T, Miederer I, Henriksen G, Yousefi BH, Graner P, Wester HJ, Förstl H, Kurz A, Dickerson BC, Bartenstein P, Drzezga A. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. *Biol Psychiatry* 2011. doi:10.1016/j.biopsych.2011.04.023.
 32. Chételat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, Ellis KA, Szoek C, Martins RN, O'Keefe GJ, Salvado O, Masters CL, Rowe CC. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. *Ann Neurol* 2010;67(3):317–24. doi:10.1002/ana.21955.
 33. Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA. Amyloid-beta associated cortical thinning in clinically normal elderly. *Ann Neurol* 2011;69(6):1032–42. doi:10.1002/ana.22333.
 34. Jack Jr CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnesic mild cognitive impairment. *Brain* 2008;131(Pt 3):665–80.
 35. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, Irizarry MC, Klunk WE, Mathis CA, Dekosky ST, Greenberg SM, Hyman BT, Growdon JH. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. *Arch Neurol* 2007;64(3):431–4.
 36. Ikonovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolkowski S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. *Brain* 2008;131(Pt 6):1630–45.
 37. Cairns NJ, Ikonovic MD, Benzinger T, Storandt M, Fagan AM, Shah A, Schmidt RE, Perry A, Reinwald LT, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. *Arch Neurol* 2009;66(12):1557–62.
 38. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. *Neurology* 2010;74(1):77–84.
 39. Villemagne VL, McLean CA, Reardon K, Boyd A, Lewis V, Klug G, Jones G, Baxendale D, Masters CL, Rowe CC, Collins SJ. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. *J Neurol Neurosurg Psychiatry* 2009;80:998–1001.
 40. Sojkova J, Driscoll I, Iacono D, Zhou Y, Codispoti KE, Kraut MA, Ferrucci L, Pletnikova O, Mathis CA, Klunk WE, O'Brien RJ, Wong DF, Troncoso JC, Resnick SM. In vivo fibrillar β -amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. *Arch Neurol* 2011;68(2):232–40.
 41. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman PE, Zehntner SP, Skovronsky DM. Use of florbetapir-PET for imaging beta-amyloid pathology. *JAMA* 2011;305(3):275–83.
 42. Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Nägren K, Tapiola T, Pirttilä T, Rinne J, Jääskeläinen JE, Soininen H, Rinne JO. Assessment of β -amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. *Arch Neurol* 2008;65(10):1304–9.
 43. Kadir A, Marutle A, Gonzalez D, Schöll M, Almkvist O, Mousavi M, Mustafiz T, Darreh-Shori T, Nennesmo I, Nordberg A. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. *Brain* 2011;134(Pt 1):301–17.
 44. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, Dekosky ST, Caselli RJ. Fibrillar amyloid- β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. *Proc Natl Acad Sci U S A* 2009;106:6820–5.
 45. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. *Ann Neurol* 2010;67(1):122–31.

46. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Frupp J, Tochon-Danguy H, Morandau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoek C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. *Neurobiol Aging* 2010;31(8):1275–83.
47. Fagan AM, Holtzman DM. Cerebrospinal fluid biomarkers of Alzheimer's disease. *Biomark Med* 2010;4(1):51–63.
48. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolkowski SK, Bi W, Hoge JA, Cohen AD, Ikonomic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. *J Neurosci* 2007;27(23):6174–84.
49. Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, Jones G, Watanabe Y, Mulligan R, Nakagawa M, Miki T, Shimada H, O'Keefe GJ, Masters CL, Mori H, Rowe CC. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. *Arch Neurol* 2009;66(12):1537–44. doi:10.1001/archneurol.2009.285.
50. Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, Nägren K, Rokka J, Haaparanta M, Kalimo H, Rinne JO. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. *Brain* 2008;131(Pt 7):1845–53.
51. Villemagne VL, Pike K, Pejoska S, Boyd A, Power M, Jones G, Masters CL, Rowe CC. 11C-PiB PET ABri imaging in Worster-Drought syndrome (familial British dementia): a case report. *J Alzheimers Dis* 2010;19(2):423–8. doi:10.3233/JAD-2010-1241.
52. Ng SY, Villemagne VL, Masters CL, Rowe CC. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. *Arch Neurol* 2007;64(8):1140–4. doi:10.1001/archneur.64.8.1140.
53. Formaglio M, Costes N, Seguin J, Tholance Y, Le Bars D, Roullet-Solignac I, Mercier B, Krolak-Salmon P, Vighetto A. In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings. *J Neurol* 2011;258(10):1841–51. doi:10.1007/s00415-011-6030-0.
54. Kambe T, Motoi Y, Ishii K, Hattori N. Posterior cortical atrophy with [11C] Pittsburgh compound B accumulation in the primary visual cortex. *J Neurol* 2010;257(3):469–71. doi:10.1007/s00415-009-5377-y.
55. Tenovuo O, Kempainen N, Aalto S, Nägren K, Rinne JO. Posterior cortical atrophy: a rare form of dementia with in vivo evidence of amyloid-beta accumulation. *J Alzheimers Dis* 2008;15(3):351–5.
56. Dierksen GA, Skehan ME, Khan MA, Jeng J, Nandigam RN, Becker JA, Kumar A, Neal KL, Betensky RA, Frosch MP, Rosand J, Johnson KA, Viswanathan A, Salat DH, Greenberg SM. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. *Ann Neurol* 2010;68(4):545–8. doi:10.1002/ana.22099.
57. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith EE, Rosand J, Rentz DM, Klunk WE, Mathis CA, Price JC, Dekosky ST, Fischman AJ, Greenberg SM. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. *Ann Neurol* 2007;62(3):229–34.
58. Ikonomic MD, Klunk WE, Abrahamson EE, Wu J, Mathis CA, Scheff SW, Mufson EJ, DeKosky ST. Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease. *Neurology* 2011;77(1):39–47.
59. Mufson EJ, Binder L, Counts SE, Dekosky ST, Detolledo-Morrell L, Ginsberg SD, Ikonomic MD, Perez SE, Scheff SW. Mild cognitive impairment: pathology and mechanisms. *Acta Neuropathol* 2011.
60. Klunk WE, Lopresti BJ, Ikonomic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. *J Neurosci* 2005;25(46):10598–606.
61. Svedberg MM, Hall H, Hellström-Lindahl E, Estrada S, Guan Z, Nordberg A, Långström B. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. *Neurochem Int* 2009;54(5–6):347–57. doi:10.1016/j.neuint.2008.12.016.
62. Hutchens TW, Li CM. Ligand-binding properties of estrogen receptor proteins after interaction with surface-immobilized Zn(II) ions: evidence for localized surface interactions and minimal conformational changes. *J Mol Recognit* 1990;3(4):174–9.
63. Takami M, Kasuya I, Tsunoo H. A ligand-receptor binding assay by receptor immobilization. *Anal Biochem* 1988;170(1):238–42.
64. Schuck P. Kinetics of ligand binding to receptor immobilized in a polymer matrix, as detected with an evanescent wave biosensor. I. A computer simulation of the influence of mass transport. *Biophys J* 1996;70(3):1230–49.
65. Toyama H, Ye D, Ichise M, Liow JS, Cai L, Jacobowitz D, Musachio JL, Hong J, Crescenzo M, Tipre D, Lu JQ, Zoghbi S, Vines DC, Seidel J, Katada K, Green MV, Pike VW, Cohen RM, Innis RB. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. *Eur J Nucl Med Mol Imaging* 2005;32(5):593–600.
66. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, Staufenbiel M, Iwata N, Ono M, Saido TC, Suzuki K, Mori H, Higuchi M, Suhara T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. *J Neurosci* 2007;27(41):10957–68.
67. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, Imagawa M, Ataka S, Wada Y, Yoshioka E, Nishizaki T, Watanabe Y, Mori H. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. *Ann Neurol* 2008;63(3):377–87.
68. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, Libri V, Leppert D, Beach TG. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. *Brain* 2007;130(Pt 10):2607–15.
69. Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez K, Cortés M, Culvenor JG, Li QX, Laughton KM, Rowe CC, Masters CL, Cappai R, Villemagne VL. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. *J Neurosci* 2007;27(39):10365–71. doi:10.1523/JNEUROSCI.0630-07.2007.
70. Ye L, Velasco A, Fraser G, Beach TG, Sue L, Osredkar T, Libri V, Spillantini MG, Goedert M, Lockhart A. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. *J Neurochem* 2008;105(4):1428–37.
71. Anonymous. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. *Neurobiol Aging* 1997;18(4 Suppl):S1–2.
72. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 1991;41(4):479–86.
73. Khachaturian ZS. Diagnosis of Alzheimer's disease. *Arch Neurol* 1985;42(11):1097–105.

74. Levine 3rd H, Walker LC. Molecular polymorphism of Abeta in Alzheimer's disease. *Neurobiol Aging* 2010;31(4):542–8.
75. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. *Nat Med* 2011;17(9):1060–5.
76. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD, Weissfeld LA, Mathis CA, Klunk WE, DeKosky ST. Amyloid imaging in mild cognitive impairment subtypes. *Ann Neurol* 2009;65(5):557–68.
77. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Långström B, Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. *Neurobiol Aging* 2008;29(10):1456–65.
78. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ. Conversion of amyloid positive and negative MCI to AD over 3years: an 11C-PIB PET study. *Neurology* 2009;73(10):754–60.
79. Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. *Ann Neurol* 2011;69(1):181–92. doi:10.1002/ana.22248.
80. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. *Br J Psychiatry* 1968;114(512):797–811.
81. Jack Jr CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol* 2010;9(1):119–28. doi:10.1016/S1474-4422(09)70299-6.
82. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. *Proc Natl Acad Sci U S A* 2011;108(14):5819–24.
83. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat Med* 2008;14(8):837–42.
84. Stern Y. Cognitive reserve and Alzheimer disease. *Alzheimer Dis Assoc Disord* 2006;20(3 Suppl 2):S69–74.
85. Roe CM, Mintun MA, D'Angelo G, Xiong C, Grant EA, Morris JC. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. *Arch Neurol* 2008;65(11):1467–71.
86. Glenner GG. Alzheimer's disease. The commonest form of amyloidosis. *Arch Pathol Lab Med* 1983;107:281–2.
87. Klunk WE. Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. *Neurobiol Aging* 2011;32 Suppl 1:S20–36. doi:10.1016/j.neurobiolaging.2011.09.006.
88. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Långström B, Nordberg A. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. *Brain* 2006;129(Pt 11):2856–66.
89. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O'Keefe G, Någren K, Chaudhury KR, Masters CL, Brooks DJ. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. *J Neurol Neurosurg Psychiatry* 2008;79(12):1331–8. doi:10.1136/jnnp.2007.127878.
90. Drzezga A, Grimmer T, Henriksen G, Stangier I, Pernecky R, Diehl-Schmid J, Mathis CA, Klunk WE, Price J, DeKosky S, Wester HJ, Schwaiger M, Kurz A. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. *Neuroimage* 2008;39(2):619–33.